| 1 |
33907665 | Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients? | 2021 |
1 |
| 2 |
21612106 | [Nonsteroidal antirheumatics and hypertension]. | 2011 Mar-Apr |
1 |
| 3 |
16004891 | Angiotensin-converting enzyme inhibitors reveal non-NO-, non-prostacycline-mediated endothelium-dependent relaxation in internal thoracic artery of hypertensive patients. | 2005 Jul 20 |
2 |
| 4 |
12494116 | [Interaction of angiotensin converting enzyme inhibitors with nonsteroidal antiinflammatory drugs]. | 2002 |
1 |
| 5 |
10828759 | Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. | 2000 Apr |
1 |
| 6 |
11078175 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. | 2000 Nov |
2 |
| 7 |
9848785 | The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. | 1998 Dec |
1 |
| 8 |
9853274 | Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. | 1998 Dec |
1 |
| 9 |
9060089 | PGE2 production after angiotensin-converting enzyme inhibition. | 1997 Feb |
2 |
| 10 |
9289376 | [The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors]. | 1997 Jun |
2 |
| 11 |
2175149 | Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. | 1990 |
2 |
| 12 |
3005063 | [Clinical significance of serum angiotensin I-converting enzyme in essential hypertension]. | 1985 Dec 20 |
1 |